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ABSTRACT
It is assumed that long-established research findings and internationally accepted evidence should, and will, be translated into policy and
practice. Knowledge about what prevents harm and promotes health has, in fact, guided and resulted in numerous beneficial public health
actions. However, such is not always the case. The authors examine three notable, and unwelcome, exceptions in the UK—all in the field of
reproductive health and all focused on the period prior to pregnancy. The three examples of counterproductive inaction discussed are: fortifying
flour with Vitamin B9 (folic acid); preventing foetal alcohol spectrum disorders; and reducing risks and better regulating a highly teratogenic
medication (valproate). The adverse consequences, as well as the causes, of inaction are analysed for each example. Reasons for optimism, and
recommendations for overcoming inaction, are also offered, in particular, greater priority should be accorded to preconception health,
education and care.
Keywords evidence-based policy, fetal alcohol spectrum disorders (FASD), folic acid, preconception health, (public) health policy, pregnancy,
prevention of birth defects, reproductive health, valproate
Public health has a long and generally proud history of pro-
tecting populations from serious harm, preventing predict-
able dangers, minimizing unreasonable risks and intervening
to solve major collective crises.1 Some public health mea-
sures have been instigated under extraordinary pressures—
e.g. the rapid spread of little-known diseases—on the basis
of educated guesswork and/or applying the Precautionary
Principle, rather than scientific certainty.2–5
Sometimes, the choice has been made not to act at all.
The reasons for not acting range from well-founded con-
cerns about violating the fundamental principle ‘first, do no
harm’ to the presence of genuinely contradictory evidence in
relation to the proposed measure. Under such circum-
stances, restraint is usually the better part of wisdom.6
In contrast, the focus of this article is on public health
actions that should have been implemented in Scotland (and
the rest of the UK) years ago, but were not. In this overview,
we explore the drivers of inaction within our society, and
especially by our public bodies, when extensive scientific
evidence has long justified preventive policies that have not
been pursued.
The three illustrations of such inaction considered here are:
• Fortifying flour with vitamin B9 (folic acid);
• preventing fetal alcohol spectrum disorders (FASD); and
• valproate risk reduction and prescribing regulations.
Each of these examples has a unique history, but they share
three characteristics. First, international evidence favouring
these public health actions is long-standing and rock-solid;
second, they all speak to the rights, empowerment and well-
being of women of childbearing potential (and to a lesser
extent, prospective fathers); and, third, the adverse impacts
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of inaction are much more frequent and more profound
than acknowledged.
Profiles in procrastination
Case 1: Not fortifying flour with vitamin B9
Ironies abound in this example. A total of 80 countries
around the world mandate the fortification of flour, or
another staple grain, with vitamin B9 (folic acid)—but not
the UK.7 This is true even though the British Medical
Research Council funded the still-lauded, 1991 randomized
control trial that provided the scientific foundation for inter-
national fortification.8 Following 2 decades of closely moni-
tored implementation, no country has ever had cause to
discontinue mandatory vitamin B9 food fortification.
The justification for significantly increasing women’s
blood folate levels prior to conception is beyond scientific
doubt. An adequate level of folate (primarily from folic acid)
prevents more than two-thirds of neural tube defects
(NTDs). But, the preventative benefit is achieved only if that
higher level is reached during the months before conception
and at least the first month of pregnancy (when the neural
tube forms).9 NTDs include not only spina bifida and four
forms of disordered brain development among live births,
but also lead to miscarriages, voluntary terminations, still-
births and infant deaths.
Only a minority of prospective mothers have adequate
folate levels at the start of their pregnancy—almost always
the result of an extended, daily, individual regimen of vita-
min B9 (folic acid) supplementation.10 Among women of
childbearing potential, the prevention benefits are realized
less frequently by those with low socioeconomic status. This
inequality is exacerbated by the fact that roughly half of all
UK pregnancies are unintended or mistimed. Twenty years
of actively promoting ‘voluntary supplementation’ has not
succeeded.11
For the sake of both primary prevention and reducing
inequalities, the solution is to mandate vitamin B9 fortifica-
tion of all wheat (but not wholegrain) flour and/or other
grains. This still allows consumers to choose non-fortified
products and voluntary supplementation, if they prefer.
The lead researcher for the original 1991 RCT is Dr
Nicholas Wald, later honoured with a knighthood for his
contributions to global public health. And yet, Professor Sir
Nicholas’ advice to mandate fortification of flour with vita-
min B9—as a matter of urgency—has been ignored for
more than 25 years within the UK.12
Major new research from Wald et al.13 removes the last
medical-minority doubt about folic acid fortification. It
reveals that fears of an ‘overdose’ are groundless, as there
are no ill effects from ingesting any plausible level of vitamin
B9—bodies merely eliminate any excess.
Repeatedly, and in great detail, the UK’s Food Standards
Agency’s own Scientific Advisory Council on Nutrition
(SACN) has examined the evidence on the pros and cons of
fortification. It also assessed the evidence from all the coun-
tries mandating fortification. Each time, SACN has publicly
endorsed adding vitamin B9 to flour without reservation—
but also without success.14
The final irony is that the UK has already mandated and
implemented the fortification of (non-wholegrain) wheat
flour with four health-promoting ingredients—including
both vitamin B1 (thiamine) and B3 (niacin)—for more than
half a century.15
Case 2: Minimizing the existence and importance
of foetal alcohol harm
Starting with the 18th century Gin Act, UK governments and
campaigners have tried to reduce alcohol harm. However, this
general aspiration rarely extended to discouraging alcohol
consumption during pregnancy. In fact, alcohol was used to
offset some gestational symptoms.16,17
The term ‘Fetal Alcohol Syndrome’ first appeared in ‘The
Lancet’ in 1973.18 Following up in Scotland, Dr Forrester
Cockburn, Professor of Child Health at Glasgow University/
Yorkhill Hospital, co-authored a 1983 article in the ‘British
Medical Journal’ on the dozens of FAS cases quickly con-
firmed locally.19 The entire topic then virtually disappeared
from the medical literature and health policy for more than 2
decades in Scotland/UK.20
Over the next 35 years, full-blown FAS came to be under-
stood as constituting only ~10% of cases of the much broader
entity, FASD.21 There is longstanding scientific agreement that
alcohol is a teratogenic agent, passing easily through the pla-
centa, un-metabolized by the foetus. Among those affected, the
harm typically includes irreversible neurodevelopmental, cogni-
tive and behavioural impairment.22,23
Amidst recent attention to ‘Scotland’s unhealthy relation-
ship with alcohol’—including landmark minimum unit pricing
legislation implemented in Scotland in 2018—FASD is men-
tioned only in passing.24,25 This FASD policy vacuum is espe-
cially noteworthy given that women in Scotland and the rest
of the UK are equal consumers of alcohol in the heaviest-
drinking World Health Organization region.26 FASD remains
a cultural, professional and governmental ‘blind spot’ allowing
foetal alcohol harm and its lifelong consequences to continue
unabated. Even minimum unit pricing may not solve the
problem.27
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Case 3: Failing to control access to, and gain informed
consent about, valproate prescribing for women of
reproductive age
French scientists serendipitously discovered in the early 1960s
that valproate had anti-seizure properties. The US Food and
Drug Administration (FDA) first approved it as an epilepsy
medication 40 years ago (1978). The reality was confirmed
in the 1980s that valproate was an especially powerful ter-
atogen—with up to 40% of exposures during pregnancy
resulting in significant physical and neurodevelopmental birth
defects.28 Thus, the basis for informing, counselling and con-
trolling access to valproate among women of childbearing
potential has been known for at least 25 years.29
Across the UK, many women having epilepsy and pre-
scribed valproate have received ‘preconception’ counselling
(including switching medications pre-pregnancy). Similarly,
no competent doctor would ‘start’ prescribing valproate to a
visibly pregnant woman. There are automatic warnings and
contraindications built into the prescribing system.
Recently, a widespread, clear warning has been issued
across the UK against prescribing valproate, for any reason,
to women of childbearing potential.30 And yet, in recent
years, 92 000 valproate prescriptions annually have been
given to young girls and women of childbearing age, in
England alone.31
Recent public outcry in France has now reached the
European Medicines Agency (EMA).31,32 The EMA held its
first-ever Public Hearing in September 2017 to address pro-
blems and possible solutions related to valproate.33 In 2018,
the EMA, and subsequently the UK Government and Irish
legislature, finally recommended significantly stronger mea-
sures to reduce exposure to valproate during pregnancy
(ranging from clearer warnings to better informed consent
procedures) and prior to conception (e.g. risk assessments,
counselling and contraception as needed, while taking val-
proate).34–36
These are welcome steps forward, but they beg the ques-
tion: ‘Why were not such sensible public health measures
implemented over the past 3 decades, since the requisite sci-
entific knowledge was already firmly in place?’37
The price of passivity
It is one thing to refrain from initiating public health and
clinical actions when credible evidence and understanding
are sparse or contradictory. But, it is quite another to have
had so much certainty for so long, and yet fail to act.
Major and enduring damage was done in the UK over the
past decades to the thousands of people (both living and
dead) who have been affected by preventable NTDs, FASD
and exposure to valproate in utero.38–40 There is no cure for
spina bifida, anencephaly or other NTDs; no one ‘outgrows’
foetal alcohol harm; and, none of the valproate-induced birth
defects are fully rectifiable.
Adding insult to injury, ‘secondary effects’ associated with
each of these birth defects compromise lives and life
chances.41 For instance, victims can experience stigmatiza-
tion, bullying, or exclusion from school. Their parents, sib-
lings, family members and carers have also had their work,
personal and economic lives radically changed by their
responsibilities toward those with FASD, NTDs or foetal
valproate harm. Adverse pregnancy outcomes (e.g. miscar-
riages) also come with a significant human cost.
The high financial/economic burdens associated with
NTDs, FASD and valproate-harm have been formally but
incompletely estimated—e.g. the familiar reference to ‘mil-
lion dollar FASD babies’ in Canada.42 Beyond these tangible
burdens on the public purse and the human costs noted
above, there is a broader professional and societal price tag
for inaction, including loss of confidence in public health
policymakers and practitioners, and questioning their com-
mitment to reproductive health and primary prevention.
The causes of inaction
We suggest that prolonged inaction on these pregnancy-
related public health measures can best be explained by cul-
tural factors in Scotland and the rest of the UK. ‘Cultural’ in
this context refers to the ‘prevailing’ beliefs, values, assump-
tions, social norms, traditions, language, attitudes and social-
ization processes that shape collective thinking, reactions
and actions.
‘First, the UK’s public policy apparatus operates in a fun-
damentally reactive, crisis-driven manner—and FASD,
NTDs and valproate misuse have not been perceived by the
“powers that be” as crises.’ A hallmark of the current era is
a recurring series of inquiries to apologize for, and ‘learn les-
sons’ from, numerous crises—from child sexual abuse to
the Grenfell Tower fire—that were predicted, but not pre-
vented. The UK’s cultural definition of ‘heroism’ and ‘lead-
ership’ is deeply rooted in the idea of taking bold actions to
deal with an out-of-control crisis.43
There is plenty of rhetorical support in favour of primary
prevention and preventative spending, but that is neither
honoured nor reflected in the actual distribution of human,
institutional and financial resources and rewards. Scotland’s
respected 2011 Christie Commission on the Future Delivery
of Public Services concluded that 40% of all public expendi-
tures were driven by ‘failure demand’, i.e. reacting after the
fact when prevention would have been wiser and less
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expensive.44 Due to the combination of austerity and recession
—two crisis-provoking events—that percentage has subse-
quently risen.45
‘Second, there is an abiding cultural discomfort with sex-
ual/reproductive matters; the UK has not fully disentangled
itself from a global tendency of not prioritizing things related
to pregnancy/parenthood—perhaps because they are con-
sidered as “women’s business”.’46 This reflects intrinsic sex-
ism and the remnants of a patriarchal society (e.g. the
inclination to blame women, rather than empower and sup-
port them in relation to their own reproductive goals/lives).
It is neither inevitable, nor a coincidence, that roughly
50% of UK pregnancies are unintended or mistimed—and
that nearly one in six pregnancies are terminated (higher in
England than Scotland).47 Most UK babies are conceived in
the context of ambivalence about, and/or lack of prepar-
ation for, parenthood. This means fundamental questions
frequently go both unasked and unanswered. As a culture,
the UK exhibits an extraordinarily ‘laissez faire’ attitude
toward preparing and supporting the next generation of
mothers and fathers.
‘Third, our three illustrations shine different lights on
how language can undermine desirable outcomes.’ Wording
matters in the flour ‘fortification’ debate. ‘Folic acid’ may
not have been as good a choice for reassuring policymakers
and the public as ‘vitamin B9’. Adding a vitamin to our food
sounds more benign than adding an acid. That may help
explain why ‘niacin’ (vitamin B3)—rather than the more
ominous-sounding chemical name for it, ‘nicotinic acid’—
has been added uncontroversially to UK baked goods for
half a century.
Valproate also offers a lesson about terminology. Current
attempts to alert the public about significant, proven risks of
taking valproate during pregnancy often forget that women of
childbearing potential are rarely prescribed generic ‘valproate’.
Instead, women in Europe perceive themselves as taking one
of the 30+ brand-name versions of valproate (from Absenor
to Hexaquin). For many people, it is challenging to remember
brand names, let alone the active ingredient(s). This represents
a crucial and dangerous linguistic disconnect.
‘Fourth, the UK’s relatively non-litigious culture—while a
blessing in many respects—may have removed one powerful
motivation for implementing these three public health mea-
sures.’ Samuel Johnson’s famous 18th century observation
—‘Depend upon it, sir, when a man knows he is to be
hanged in a fortnight, it concentrates his mind wonderfully.’—
may be applicable here today. If the chances of being sued,
charged with an offence, publicly shamed or held accountable
in other meaningful ways for failing to act are minimal, then
the impetus to implement is significantly diminished.
‘Fifth, there continues to be ‘wilful ignorance’ across
Scotland and the rest of the UK about the prevalence of
FASD, NTD-affected pregnancies and valproate-related
birth defects.’ The absence of Scottish/UK epidemiological
evidence—and other data about the consequences/costs—
of all three problems is a choice, not an inevitability.
Ignorance has not been ‘bliss’ for those harmed by this
choice.48
Replacing inaction with accomplishment
If cultural factors best explain why these three public health
measures should have been implemented—but have not—
then focusing on the cultural side seems the most likely way
to achieve a different, better result.
We see several reasons for optimism.
• Citizens’/victims groups have very recently persuaded
both the mass media and politicians to take seriously the
prevention of valproate exposure during pregnancy. Some
of the language from top politicians suggests an under-
lying cultural shift. The UK’s Health Secretary in
February 2018 told the Westminster Parliament that: ‘We
must acknowledge that the response to these issues from
those in positions of authority has not always been good
enough. Sometimes the reaction has felt too focused on
defending the status quo.’49
• Scotland’s Chief Medical Officer has been championing
the concept of ‘Realistic Medicine’ with widespread
national/international agreement and a growing number
of examples in practice.50 This is explicitly a cultural shift
based upon six principles, including: ‘shared decision-
making’; a ‘whole person approach’; and, ‘better managing
risks’. The CMO notes: ‘… just as opinion coalesced
around the advent of professionalism in the 19th century,
there exists a broad international movement… to co-
create health between practitioners and citizens as an
inviolable standard.’51
• Scotland’s Minister of Public Health launched an explor-
ation of using devolved powers to ‘go it alone’, if the UK
continues to refuse mandatory vitamin B9 fortification.
Acknowledging that UK-wide legislation is best, this
Minister (and her Welsh counterpart) jointly urged the
UK Health Secretary to act in late 2017 and again in
2018.52,53 An earlier Member’s Bill to fortify flour was
passed by the House of Lords, but disappeared when the
Prime Minister dissolved Parliament for a snap election.54
A 2018 Westminster debate may revive its prospects.55
• Particularly in Scotland, modest steps have been taken,
and more are underway to prevent, identify and treat
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FASD. These range from the only online NHS course/
resource for all professionals on foetal alcohol harm—
through the planned 2018 publication on FASD clinical
practice from the Scottish Intercollegiate Guidelines
Network (SIGN)—to the first recognition of FASD in
statutory guidance since Scotland enacted the Additional
Support for Learning Act 2004.56,57
• There are Scottish/UK models of building broad coalitions
to resolve other key public health issues. These brought
together government, voluntary, academic, media and pri-
vate sectors, as well as individual champions in effective
and sustained ways. These successful precedents achieved
major changes in culture, law, policy and practice—such as
reducing drink driving, the smoking ban and violence
reduction (especially knife crime)—and should encourage
and inform similar public health efforts around NTDs,
FASD and valproate exposure.
• The relevant precedents are not limited to public health,
as there is a great deal to learn, and adapt, from other
profound social/cultural movements that sparked change.
These include lessons from the history of science and
medicine, but especially from the women’s rights move-
ment and the children’s rights movement. The whole
‘rights’ ethos provides a useful foundation for building
both an individual sense of agency and a collective sense
of responsibility to prevent harm and promote wellbeing/
equity.
Prioritizing preconception health
The biggest still-missing element in overcoming long-
standing inaction on these three public health measures is
a movement in favour of—and culture changes that give
priority to—preconception health, education and care
across the life course.58–60 There is an antenatal compo-
nent to each of the three examples, but they all require
much more attention to what happens (or fails to happen)
prior to pregnancy.
That, in turn, requires a cultural change beyond the trad-
itional binary choice between either avoiding pregnancy or
being pregnant. There are two additional, often-overlooked
stages between ‘not pregnant’ and ‘pregnant’. One is being
ready, willing and able to make empowered, informed
choices about whether and when to become a parent. The
other is preparing for pregnancy.61 A society that takes pre-
conception (before the first pregnancy) and interconception
(before the next pregnancy) seriously is one in which
inaction on NTDs, FASD and valproate would not be tol-
erated or perpetuated.62
Achieving safer pregnancies and thriving babies is within
reach here and now. The key is finally taking robust action
on these public health measures. The next generation
deserves no less.
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